Skip to Content

IR Biosciences Holdings Inc IRBS

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

IR Biosciences Holdings Inc is a development-stage biotechnology company engaged in the research & development of potential drug candidate, Homspera and its derivatives, Radilex and Viprovex through its subsidiary, ImmuneRegen BioSciences, Inc. It is engaged in the research and development of therapies in the areas of pulmonary fibrosis, influenza infection, and radiation-induced Neutropenia.

Contact
8777 E. Via De Ventura, Suite 280
Scottsdale, AZ, 85258
T +1 480 922-3926
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2010
Fiscal Year End Dec 31, 2012
Stock Type Distressed
Employees 4